CL2022003409A1 - Combiterapia de ruxolitinib con incb057643 para tratar neoplasias malignas mieloproliferativas. - Google Patents
Combiterapia de ruxolitinib con incb057643 para tratar neoplasias malignas mieloproliferativas.Info
- Publication number
- CL2022003409A1 CL2022003409A1 CL2022003409A CL2022003409A CL2022003409A1 CL 2022003409 A1 CL2022003409 A1 CL 2022003409A1 CL 2022003409 A CL2022003409 A CL 2022003409A CL 2022003409 A CL2022003409 A CL 2022003409A CL 2022003409 A1 CL2022003409 A1 CL 2022003409A1
- Authority
- CL
- Chile
- Prior art keywords
- ruxolitinib
- malignancies
- incb057643
- combination therapy
- myeloproliferative
- Prior art date
Links
- VZSAMEOETVNDQH-UHFFFAOYSA-N CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C Chemical compound CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C VZSAMEOETVNDQH-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000036210 malignancy Effects 0.000 title abstract 2
- 230000002071 myeloproliferative effect Effects 0.000 title abstract 2
- 229960000215 ruxolitinib Drugs 0.000 title abstract 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 229940088617 BET protein inhibitor Drugs 0.000 abstract 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 abstract 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 abstract 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 abstract 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034214P | 2020-06-03 | 2020-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003409A1 true CL2022003409A1 (es) | 2023-05-26 |
Family
ID=72659928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003409A CL2022003409A1 (es) | 2020-06-03 | 2022-12-01 | Combiterapia de ruxolitinib con incb057643 para tratar neoplasias malignas mieloproliferativas. |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP4161528B1 (https=) |
| JP (2) | JP7669396B2 (https=) |
| KR (1) | KR20230031242A (https=) |
| CN (1) | CN115835868A (https=) |
| AU (1) | AU2020451061A1 (https=) |
| CA (1) | CA3184633A1 (https=) |
| CL (1) | CL2022003409A1 (https=) |
| DK (1) | DK4161528T3 (https=) |
| ES (1) | ES3058891T3 (https=) |
| FI (1) | FI4161528T3 (https=) |
| HR (1) | HRP20251457T1 (https=) |
| IL (1) | IL298200A (https=) |
| LT (1) | LT4161528T (https=) |
| MA (1) | MA59868B1 (https=) |
| MD (1) | MD4161528T2 (https=) |
| MX (1) | MX2022015220A (https=) |
| PH (1) | PH12022553276A1 (https=) |
| PL (1) | PL4161528T3 (https=) |
| PT (1) | PT4161528T (https=) |
| RS (1) | RS67440B1 (https=) |
| SI (1) | SI4161528T1 (https=) |
| SM (1) | SMT202600021T1 (https=) |
| WO (1) | WO2021247064A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023009858A (es) * | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
| WO2024039883A2 (en) * | 2022-08-19 | 2024-02-22 | Translational Drug Development Llc | Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms |
| AU2024306742A1 (en) * | 2023-06-28 | 2025-12-04 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of mpn |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| PL3134403T3 (pl) * | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
-
2020
- 2020-09-14 PT PT207812025T patent/PT4161528T/pt unknown
- 2020-09-14 AU AU2020451061A patent/AU2020451061A1/en active Pending
- 2020-09-14 SI SI202030684T patent/SI4161528T1/sl unknown
- 2020-09-14 DK DK20781202.5T patent/DK4161528T3/da active
- 2020-09-14 LT LTEPPCT/US2020/050753T patent/LT4161528T/lt unknown
- 2020-09-14 KR KR1020227046429A patent/KR20230031242A/ko active Pending
- 2020-09-14 EP EP20781202.5A patent/EP4161528B1/en active Active
- 2020-09-14 FI FIEP20781202.5T patent/FI4161528T3/fi active
- 2020-09-14 CA CA3184633A patent/CA3184633A1/en active Pending
- 2020-09-14 JP JP2022574520A patent/JP7669396B2/ja active Active
- 2020-09-14 HR HRP20251457TT patent/HRP20251457T1/hr unknown
- 2020-09-14 EP EP25209713.4A patent/EP4691563A3/en active Pending
- 2020-09-14 IL IL298200A patent/IL298200A/en unknown
- 2020-09-14 MD MDE20230400T patent/MD4161528T2/ro unknown
- 2020-09-14 WO PCT/US2020/050753 patent/WO2021247064A1/en not_active Ceased
- 2020-09-14 MX MX2022015220A patent/MX2022015220A/es unknown
- 2020-09-14 ES ES20781202T patent/ES3058891T3/es active Active
- 2020-09-14 PH PH1/2022/553276A patent/PH12022553276A1/en unknown
- 2020-09-14 SM SM20260021T patent/SMT202600021T1/it unknown
- 2020-09-14 MA MA59868A patent/MA59868B1/fr unknown
- 2020-09-14 RS RS20251189A patent/RS67440B1/sr unknown
- 2020-09-14 CN CN202080101656.6A patent/CN115835868A/zh active Pending
- 2020-09-14 PL PL20781202.5T patent/PL4161528T3/pl unknown
-
2022
- 2022-12-01 CL CL2022003409A patent/CL2022003409A1/es unknown
-
2025
- 2025-04-16 JP JP2025067272A patent/JP2025111539A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL298200A (en) | 2023-01-01 |
| LT4161528T (lt) | 2026-02-10 |
| SI4161528T1 (sl) | 2026-01-30 |
| EP4691563A2 (en) | 2026-02-11 |
| JP2023529365A (ja) | 2023-07-10 |
| PH12022553276A1 (en) | 2024-02-19 |
| EP4161528A1 (en) | 2023-04-12 |
| JP7669396B2 (ja) | 2025-04-28 |
| CN115835868A (zh) | 2023-03-21 |
| FI4161528T3 (fi) | 2025-12-12 |
| MX2022015220A (es) | 2023-03-08 |
| WO2021247064A1 (en) | 2021-12-09 |
| RS67440B1 (sr) | 2025-12-31 |
| DK4161528T3 (da) | 2025-11-24 |
| HRP20251457T1 (hr) | 2026-01-02 |
| PT4161528T (pt) | 2026-01-23 |
| SMT202600021T1 (it) | 2026-03-09 |
| ES3058891T3 (en) | 2026-03-13 |
| AU2020451061A1 (en) | 2022-12-15 |
| CA3184633A1 (en) | 2021-12-09 |
| EP4691563A3 (en) | 2026-04-01 |
| KR20230031242A (ko) | 2023-03-07 |
| JP2025111539A (ja) | 2025-07-30 |
| MD4161528T2 (ro) | 2026-03-31 |
| PL4161528T3 (pl) | 2026-03-16 |
| MA59868B1 (fr) | 2025-11-28 |
| EP4161528B1 (en) | 2025-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003409A1 (es) | Combiterapia de ruxolitinib con incb057643 para tratar neoplasias malignas mieloproliferativas. | |
| CO2024006030A2 (es) | Compuestos de quinolina como inhibidores de kras | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2021002651A2 (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met | |
| UY37149A (es) | 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas | |
| ECSP22061711A (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos | |
| MX2021007468A (es) | Compuestos que participan en la union cooperativa y usos de los mismos. | |
| ECSP034916A (es) | Oxazolidinonas substituidas para terapia de combinacion | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| BRPI0707189A8 (pt) | derivados de pirimidina utilizados como inibidores de pi-3 cinase | |
| CR9650A (es) | Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms | |
| ECSP22009803A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas | |
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| PA8647401A1 (es) | 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, | |
| CL2023001637A1 (es) | Inhibidores de la vía jak1 para el tratamiento del vitíligo. | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| MX2021008903A (es) | Compuestos y usos de los mismos. | |
| MX2024015077A (es) | Benzopirimidina-4(3h)-onas como inhibidores de pi3k | |
| CO2022016153A2 (es) | Inhibidores de il4i1 y métodos de uso | |
| BR112022024794A2 (pt) | Hexahidropirrolo[3,4-b]pirrolo-5(1h)-carbonitrilas com atividade como inibidores de usp30 para uso no tratamento de disfunção mitocondrial, câncer e fibrose | |
| AR051472A1 (es) | Uso de inhibidores de las quinasas jun n- terminales para eltratamiento de la retinopatia glaucomatosa y enfermedades oculares | |
| CL2024003731A1 (es) | Compuestos tricíclicos de triazolo, inhibidores de dgk; uso para tratar cáncer. | |
| MX2021011799A (es) | Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer. | |
| ATE388151T1 (de) | Trizyklische purin derivate und deren analoga als inhibitoren des cytokinsignals |